Research programme: antibody therapeutics - Adimab/Merck & Co

Drug Profile

Research programme: antibody therapeutics - Adimab/Merck & Co

Latest Information Update: 04 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Adimab; Merck & Co
  • Class Antibodies; Bispecific antibodies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Unspecified

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for research development in Undefined in USA (Parenteral)
  • 12 Jan 2016 Antibody discovery and optimisation technology licensed to Merck
  • 08 Jan 2013 Adimab and Merck expand their collaboration
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top